We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
salesforce (CRM) Q4 Earnings: Can it Sustain its Earnings Streak?
Read MoreHide Full Article
salesforce.com Inc. (CRM - Free Report) is slated to release fourth-quarter fiscal 2019 results on Mar 4.
Notably, the company delivered a positive surprise in all the trailing four reported quarters, the average being 35%.
In the last reported quarter, it came up with non-GAAP earnings of 61 cents per share, comprehensively exceeding the Zacks Consensus Estimate of 50 cents and also the year-ago quarter’s figure of 39 cents.
Revenues of $3.39 billion improved 26% year over year and also surpassed the Zacks Consensus Estimate of $3.37 billion. Moreover, the top line rose 26% at constant currency (cc). Additionally, the rapid adoption of the company’s cloud-based solutions led to the better-than-expected results.
What to Expect in Q4
For fourth-quarter fiscal 2019, revenues are projected between $3.551 billion and $3.561 billion, indicating a 25% increase year over year. Non-GAAP earnings are expected in the range of 54-55 cents per share.
The Zacks Consensus Estimate for earnings in the quarter to be reported is pegged at 56 cents, reflecting a year-over-year surge of 60%. The Zacks Consensus Estimate for sales of $3.56 billion indicates around 24.9% growth from the prior-year quarter.
So, let’s see how things are shaping up prior to this announcement.
Factors at Play
salesforce’s diverse cloud offerings, expanding partner base and a considerable spending on digital marketing are key growth drivers. The company’s strategy of frequent product launches and cloud services is helping it expand clientele, thereby driving top-line growth. The company continues to win customers in the international market, which in turn, is aiding it deliver strong growth internationally.
In the last reported quarter, the number of deals generating more than $1 million increased 46% year over year. Moreover, significant growth in the number of $20 million-plus deals has been the main channel of growth.
Additionally, acquisitions have always been one of salesforce’s key growth strategies, strengthening the company’s position in the customer relationship-management solution-providing space. Notably, MuleSoft’s merger with the company is a major positive. On the last earnings call, management indicated that the company will steadily invest in MuleSoft and other growth initiatives in the fiscal fourth quarter.
The company’s focus on AI and substantial progress with the launch of Einstein Analytics makes us optimistic. Moreover, salesforce's recently-unveiled Customer 360 platform is a tailwind.
salesforce’s consolidating relationships with cloud companies, namely Amazon (AMZN - Free Report) , Alphabet’s (GOOGL - Free Report) Google and International Business Machines (IBM - Free Report) among others are expected to be its key growth catalysts.
However, adverse foreign exchange volatility is a persistent overhang. The company anticipates a $200-million headwind to unearned revenues in the January quarter due to the recent strengthening of US dollar.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
salesforce (CRM) Q4 Earnings: Can it Sustain its Earnings Streak?
salesforce.com Inc. (CRM - Free Report) is slated to release fourth-quarter fiscal 2019 results on Mar 4.
Notably, the company delivered a positive surprise in all the trailing four reported quarters, the average being 35%.
In the last reported quarter, it came up with non-GAAP earnings of 61 cents per share, comprehensively exceeding the Zacks Consensus Estimate of 50 cents and also the year-ago quarter’s figure of 39 cents.
Revenues of $3.39 billion improved 26% year over year and also surpassed the Zacks Consensus Estimate of $3.37 billion. Moreover, the top line rose 26% at constant currency (cc). Additionally, the rapid adoption of the company’s cloud-based solutions led to the better-than-expected results.
What to Expect in Q4
For fourth-quarter fiscal 2019, revenues are projected between $3.551 billion and $3.561 billion, indicating a 25% increase year over year. Non-GAAP earnings are expected in the range of 54-55 cents per share.
The Zacks Consensus Estimate for earnings in the quarter to be reported is pegged at 56 cents, reflecting a year-over-year surge of 60%. The Zacks Consensus Estimate for sales of $3.56 billion indicates around 24.9% growth from the prior-year quarter.
So, let’s see how things are shaping up prior to this announcement.
Factors at Play
salesforce’s diverse cloud offerings, expanding partner base and a considerable spending on digital marketing are key growth drivers. The company’s strategy of frequent product launches and cloud services is helping it expand clientele, thereby driving top-line growth. The company continues to win customers in the international market, which in turn, is aiding it deliver strong growth internationally.
In the last reported quarter, the number of deals generating more than $1 million increased 46% year over year. Moreover, significant growth in the number of $20 million-plus deals has been the main channel of growth.
Additionally, acquisitions have always been one of salesforce’s key growth strategies, strengthening the company’s position in the customer relationship-management solution-providing space. Notably, MuleSoft’s merger with the company is a major positive. On the last earnings call, management indicated that the company will steadily invest in MuleSoft and other growth initiatives in the fiscal fourth quarter.
The company’s focus on AI and substantial progress with the launch of Einstein Analytics makes us optimistic. Moreover, salesforce's recently-unveiled Customer 360 platform is a tailwind.
salesforce’s consolidating relationships with cloud companies, namely Amazon (AMZN - Free Report) , Alphabet’s (GOOGL - Free Report) Google and International Business Machines (IBM - Free Report) among others are expected to be its key growth catalysts.
However, adverse foreign exchange volatility is a persistent overhang. The company anticipates a $200-million headwind to unearned revenues in the January quarter due to the recent strengthening of US dollar.
salesforce currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>